85 percent of depressed patients improve when treated with both medication and psychotherapy, study finds

May 17, 2000

In a national study of 681 chronically depressed patients, psychotherapy combined with the antidepressant Serzone improved mood in 85 percent of patients after only three months of treatment. A national research team, which included UT Southwestern Medical Center at Dallas researchers, reported their findings in today's New England Journal of Medicine.

Dr. John Rush, vice chairman for research in psychiatry, and Dr. Madhukar Trivedi, associate professor of psychiatry and principal investigator at the Dallas site, concluded that this combination therapy was overwhelmingly more effective than either medication or psychotherapy alone for treating chronic depression. Few studies have specifically addressed patients with chronic depression, and none have specifically studied psychotherapy for this group.

Trivedi said the 85 percent response rate is the highest for a three-month period for any peer-reviewed depression study. It is the largest study ever undertaken evaluating the three methods for treating chronic depression.

The research took place at a dozen outpatient psychiatric clinics and academic medical centers around the country. Patients either were treated with Serzone (nefazodone hydrochloride) twice a day, had 16 to 20 sessions of a particular type of psychotherapy (Cognitive Behavioral Analysis System of Psychotherapy, or CBASP, in which patients are taught to focus on the consequences of their behavior and to use a problem-solving approach for interpersonal difficulties) or a treatment package combining the two.

The patients in the study had each been depressed continuously for at least two years; most had experienced chronic depression for an average of 20 years. Over the 12-week study period, 55 percent of the Serzone-only group reported a positive response, and 52 percent of the CBASP-only group experienced a treatment response, whereas 85 percent of those who took both Serzone and underwent CBASP had a positive response to treatment.

Serzone is traditionally prescribed for the acute treatment of depression, as well as prevention of relapse in patients treated for depression. Those who took the drug, either alone or in combination with CBASP, reported improvement in mood much sooner than those in psychotherapy only. Patients taking Serzone did not experience the side effects of weight gain or sexual dysfunction typical of most antidepressants and reported improvement in insomnia, which is common among chronically depressed patients.

"These findings on the dual-treatment approach for the treatment of chronic depression are incredibly exciting," Trivedi said. "The large differences in response rates after only three months of treatment is truly astonishing. This approach has proven the kind of treatment we should be using with our chronically depressed patients."

The 12-week results represent the first phase of an ongoing 80-week study, which includes a 16-week trial for patients who responded positively to Serzone or the combination treatment and a 52-week maintenance phase to evaluate Serzone vs. a placebo.

Last May, preliminary findings of the Serzone Chronic Depression Study were announced at a press conference at the annual meeting of the American Psychiatric Association in Washington, D.C.

With 14 million Americans suffering from chronic depression, Trivedi hopes that insurance companies are taking note. "We expect that our findings will help with our battles about paying for the most effective treatments for depression," he said. Depression costs the U.S. economy $53 billion each year.
Dr. Martin Keller, chairman of psychiatry and human behavior at Brown University, is the study coordinator. Bristol-Myers Squibb Co., manufacturer of Serzone, funded the study.

This news release is available on our World Wide Web home page at http://www.swmed.edu/home_pages/news/

To automatically receive news releases from UT Southwestern via e-mail, send a message to UTSWNEWS-REQUEST@listserv.swmed.edu. Leave the subject line blank and in the text box, type SUB UTSWNEWS.

UT Southwestern Medical Center

Related Depression Articles from Brightsurf:

Children with social anxiety, maternal history of depression more likely to develop depression
Although researchers have known for decades that depression runs in families, new research from Binghamton University, State University of New York, suggests that children suffering from social anxiety may be at particular risk for depression in the future.

Depression and use of marijuana among US adults
This study examined the association of depression with cannabis use among US adults and the trends for this association from 2005 to 2016.

Maternal depression increases odds of depression in offspring, study shows
Depression in mothers during and after pregnancy increased the odds of depression in offspring during adolescence and adulthood by 70%.

Targeting depression: Researchers ID symptom-specific targets for treatment of depression
For the first time, physician-scientists at Beth Israel Deaconess Medical Center have identified two clusters of depressive symptoms that responded to two distinct neuroanatomical treatment targets in patients who underwent transcranial magnetic brain stimulation (TMS) for treatment of depression.

A biological mechanism for depression
Researchers report that in depressed individuals there are increased amounts of an unmodified structural protein, called tubulin, in lipid rafts compared with non-depressed individuals.

Depression in adults who are overweight or obese
In an analysis of primary care records of 519,513 UK adults who were overweight or obese between 2000-2016 and followed up until 2019, the incidence of new cases of depression was 92 per 10,000 people per year.

Why stress doesn't always cause depression
Rats susceptible to anhedonia, a core symptom of depression, possess more serotonin neurons after being exposed to chronic stress, but the effect can be reversed through amygdala activation, according to new research in JNeurosci.

Which comes first: Smartphone dependency or depression?
New research suggests a person's reliance on his or her smartphone predicts greater loneliness and depressive symptoms, as opposed to the other way around.

Depression breakthrough
Major depressive disorder -- referred to colloquially as the 'black dog' -- has been identified as a genetic cause for 20 distinct diseases, providing vital information to help detect and manage high rates of physical illnesses in people diagnosed with depression.

CPAP provides relief from depression
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.

Read More: Depression News and Depression Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.